Abstract
Drugs of abuse impact cortico-striatal dopaminergic targets and their morphology across substance types in common and unique ways. While the dorsal striatum drives addiction severity across drug classes, opiates impact ventromedial prefrontal cortex (vmPFC) and nucleus accumbens (NAcc) neuroplasticity in preclinical models, and psychostimulants alter inhibitory control, rooted in cortical regions such as the inferior frontal gyrus (IFG). We hypothesized parallel gray matter volume (GMV) changes in individuals with cocaine or heroin use disorder (CUD/HUD): decreased GMV of vmPFC/NAcc in HUD and IFG in CUD, and putamen GMV to be associated with addiction severity. We quantified GMV in age/sex/IQ-matched individuals with CUD (n=20; 5 women), HUD (n=20; 6 women), and healthy controls (HC; n=20; 5 women), further replicated in an extended sample (combined n=96). Overall, addicted individuals had smaller vmPFC volumes than HC (p<0.05-corrected), driven by HUD (p<0.05-corrected; similar NAcc reduction). Right IFG reductions were specifically evident in CUD vs. HUD (p<0.05-corrected). Posterior putamen volume increased as a function of craving in CUD vs. HUD (p<0.05-corrected). These results indicate compression of dopamine-innervated regions (in the vmPFC and NAcc) across cocaine- or heroin-addicted individuals, more severely in the latter. For the first time we demonstrate IFG compression specifically in CUD. This group also showed a unique association between craving and increased putamen volume, together indicating a signature of enhanced cue-sensitivity and habit formation. Results suggest common and substance-specific morphometry volumetric changes in human psychostimulant or opiate addiction, with implications for fine-tuning biomarker and treatment identification by primary drug of abuse.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by 1R01AT010627 and 1R01DA048301 to RZG.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Icahn School of Medicine at Mount Sinai institutional review board approved study procedures and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
